Retatrutide

Overview

Retatrutide is a first-in-class triple agonist targeting three incretin and metabolic receptors simultaneously: GLP-1, GIP, and glucagon receptors. This unprecedented triple agonism represents the next evolution in incretin pharmacology, adding glucagon receptor activation to the dual GIP/GLP-1 approach pioneered by Tirzepatide.

Early clinical trial data have shown unprecedented weight reduction results, with the glucagon component adding direct hepatic fat oxidation and thermogenic energy expenditure beyond what dual agonists achieve. This makes Retatrutide a groundbreaking research tool for studying the interplay of all three incretin and metabolic receptor pathways.

Chemical Profile

Mechanism of Action

Retatrutide simultaneously activates three metabolic receptors, each contributing distinct physiological effects. GLP-1R activation provides appetite suppression, glucose-dependent insulin secretion, and delayed gastric emptying. GIPR activation enhances beta-cell function and may improve adipocyte metabolism.

The glucagon receptor (GCGR) component distinguishes Retatrutide from dual agonists. Glucagon receptor activation in hepatocytes stimulates glycogenolysis, gluconeogenesis, and critically, hepatic fatty acid oxidation. This promotes direct energy expenditure through thermogenesis and facilitates the mobilization and oxidation of hepatic lipid stores.

The triple agonism creates a synergistic metabolic effect: GLP-1 and GIP reduce caloric intake and improve glucose handling, while glucagon increases energy expenditure and hepatic fat oxidation — addressing both sides of the energy balance equation simultaneously.

Research Applications

• Triple incretin receptor agonism pharmacology
• Unprecedented weight reduction mechanisms
• Glucagon receptor-mediated energy expenditure
• Hepatic lipid metabolism and NAFLD research
• Thermogenesis and energy expenditure
• Comparative incretin agonist studies
• Metabolic syndrome models

Handling & Reconstitution

1. 1Allow the vial and sterile water to reach room temperature (15–25°C).
2. 2Using a sterile syringe, withdraw the appropriate volume of sterile water.
3. 3Inject the water slowly along the inside wall of the vial — do not spray directly onto the powder.
4. 4Gently swirl the vial until the powder is fully dissolved. Do not shake vigorously.
5. 5Once reconstituted, store at 2°C – 8°C. Protect from light.
6. 6Use within 28 days after reconstitution.
7. 7Do not freeze reconstituted solution.